Skip to main content

Advertisement

Table 7 Ranges of estimates of costs averted by STI programs: sensitivity analyses

From: Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States

Cost estimated Upper and lower bounds obtained in simulations (10th and 90th percentiles)
Sequelae costs averted by treatment of people with chlamydia and gonorrhea Base case - 54%, Base case + 60%
Sequelae costs averted by treatment of people with syphilis Base case - 28%, Base case + 28%
Congenital syphilis treatment costs averted Base case - 36%, Base case + 39%
Treatment and sequelae costs averted by reducing STIs in the population Base case - 53%, Base case + 58%
HIV costs averted through treatment of STIs Base case - 67%, Base case + 80%
HIV costs averted by HIV counseling and testing Base case - 54%, Base case + 60%
Indirect chlamydia and gonorrhea costs averted Base case - 35%, Base case + 38%
Indirect syphilis costs averted Base case - 35%, Base case + 38%
Indirect congenital syphilis costs averted Base case - 36%, Base case + 39%
Indirect HIV costs averted through treatment of STIs Base case - 67%, Base case + 80%
Indirect HIV costs averted by HIV counseling and testing Base case - 54%, Base case + 60%